Neutropenia febril como marcador de sepsis en patologías cancerígenas

Nicolás Teatino Rubio (Autor estudiante de pregrado), Ana María Uribe Molina (Autor estudiante de pregrado)

Producción científica: Contribución a una revistaArtículo de revisión

Resumen

Febrile neutropenia in cancer patients, defined by the presence of fever together with a low absolute neutrophil count, represents a serious complication during chemotherapy, increasing the risk of serious bacterial infections such as sepsis. In addition to traditional biomarkers such as C-reactive protein and calcitonin precursor protein, new molecules such as angiopoietins, specifically angiopoietin-1 and angiopoietin-2, and related factors such as vascular endothelial growth factor are being investigated to improve the prediction and management of sepsis in this vulnerable population. Recent studies have highlighted the importance of angiopoietin-2, whose elevated levels and angiopoietin-2/angiopoietin-1 ratio have been associated with early prediction of sepsis in patients with febrile neutropenia, as well as correlating with sepsis severity and progression to septic shock. In parallel, vascular endothelial growth factor A has emerged as an indicator of sepsis progression, suggesting its potential to stratify risk and guide therapeutic decisions. The integration of these biomarkers into clinical practice would improve early identification of patients at risk of sepsis and allow personalised interventions, but further research is needed to validate their clinical utility and establish management protocols based on them. These biomarker advances promise to improve clinical outcomes and survival in patients with febrile neutropenia and to transform the sepsis approach in this vulnerable population.
Idioma originalEspañol (Colombia)
PublicaciónSalutem Scientia Spiritus
Volumen10
N.º3
EstadoPublicada - 2024
Publicado de forma externa

Tipos de Productos Minciencias

  • Artículos de divulgación

Citar esto